Therapeutic efficacy of vitamin B<sub>1</sub> for adjunctive treatment in type 2 diabetes mellitus: a meta-analysis _Chinese Journal of Evidence-Based Medicine

Authors：

LIN Wenyan ^1,2,3,4 , YAO Liang ^3,4,5 , ZHANG Qi ² , YU Jing ^1,2 , WANG Dongdong ² , LI Yang ^1,2 , LI Xiao ² , WANG Bailing ^1,2 ,  LIU Jing ² ,  YANG Kehu ^3,4,5

1. Gansu University of Chinese Medicine, Lanzhou, 730000, P.R.China;
2. Department of Endocrinology, The Gansu Provincial Hospital, Lanzhou, 730000, P.R.China;
3. Institution of Clinical Research and Evidence Based Medicine, The Gansu Provincial Hospital, Lanzhou, 730000, P.R.China;
4. Evidence Based Medicine Center, Lanzhou University, 730000, P.R.China;
5. Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, 730000, P.R.China;

Corresponding author：

LIU Jing, Email: liujing551108@126.com; YANG Kehu, Email: kehuyangebm2006@126.com

Keywords：

Vitamin B₁; Type 2 diabetes mellitus; Blood glucose; Blood pressure; Serum lipids; CRP; Randomized controlled trial; Meta-analysis

DOI：

10.7507/1672-2531.201710072

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

ObjectivesTo systematically review the therapeutic efficacy of vitamin B₁ for adjunctive treatment in type 2 diabetes mellitus.MethodsDatabases including PubMed, EMbase, The Cochrane Library, CNKI, VIP, WanFang Data and CBM were searched to collect randomized controlled trials (RCTs) on vitamin B₁ for adjunctive treatment in type 2 diabetes mellitus from inception to July 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was conducted by RevMan 5.3 and Stata 12.0 softwares. ResultsA total of 6 RCTs involving 346 patients were included. The results of meta-analysis showed that, compared with the control group, the vitamin B₁ adjunctive group had a significant improvement in CRP (MD=–1.09, 95%CI –1.63 to –0.54, P<0.000 1). However, the fasting blood glucose (MD=–0.23, 95%CI –0.58 to 0.13,P=0.22), glycosylated hemoglobin (MD=0.13, 95%CI –0.25 to 0.52, P=0.49), 2 hours plasma glucose (MD=–0.18, 95%CI –1.03 to 0.67, P=0.68), systolic pressure (MD=2.94, 95%CI –1.31 to 7.18, P=0.18), diastolic pressure (MD=–1.60, 95%CI –4.24 to 1.05, P=0.24), triglycerides (MD=–0.12, 95%CI –0.32 to 0.09, P=0.27), total cholesterol (MD=0.21, 95%CI –0.05 to 0.46, P=0.12), high-density lipoprotein cholesterols (MD=0.03, 95%CI –0.07 to 0.12, P=0.56) and low-density lipoprotein cholesterols (MD=0.12, 95%CI –0.11 to 0.35, P=0.30) had no significant differences between both groups.ConclusionsVitamin B₁ adjunctive treatment could not improve the levels of blood glucose, blood pressure and serum lipids. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.

Citation： LIN Wenyan, YAO Liang, ZHANG Qi, YU Jing, WANG Dongdong, LI Yang, LI Xiao, WANG Bailing, LIU Jing, YANG Kehu. Therapeutic efficacy of vitamin B₁ for adjunctive treatment in type 2 diabetes mellitus: a meta-analysis . Chinese Journal of Evidence-Based Medicine, 2018, 18(8): 822-830. doi: 10.7507/1672-2531.201710072 Copy

1.	Unnikrishnan R, Pradeepa R, Joshi SR, et al. Type 2 diabetes: demystifying the global epidemic. Diabetes, 2017, 66(6): 1432-1442.
2.	Dixon CJ, Knight T, Binns E, et al. Clinical measures of balance in people with type two diabetes: A systematic literature review. Gait Posture, 2017, 58: 325-332.
3.	Zabetian A, Sanchez IM, Narayan KM, et al. Global rural diabetes prevalence: a systematic review and meta-analysis covering 1990-2012. Diabetes Res Clin Pract, 2014, 104(2): 206-213.
4.	Wu C, Qiu S, Zhu X, et al. Vitamin D supplementation and glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Metabolism, 2017, 73: 67-76.
5.	Garcia-Chapa EG, Leal-Ugarte E, Peralta-Leal V, et al. Genetic epidemiology of type 2 diabetes in Mexican Mestizos. Biomed Res Int, 2017, 2017: 3937893.
6.	王海鹏. 我国诊断糖尿病疾病经济负担趋势预测研究. 济南: 山东大学, 2013.
7.	Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic pattern of diabetes and prediabetes in China in 2013. JAMA, 2017, 317(24): 2515-2523.
8.	Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes, 2017, 9(4): 320.
9.	American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care, 2015, 38(Suppl): S8-S16.
10.	Gheibi S, Kashfi K, Ghasemi A. A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin. Biomed Pharmacother, 2017, 95: 605-613.
11.	Sun W, Zhai M, Zhou Q, et al. Effects of B Vitamins overload on plasma insulin level and hydrogen peroxide generation in rats. Chin J Physiol, 2017, 60(4): 207-214.
12.	Nix WA, Zirwes R, Bangert V, et al. Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. Diabetes Res Clin Pract, 2015, 107(1): 157-165.
13.	Cetin E, Civelek S, Andican G, et al. Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy. Minerva Med, 2013, 104(1): 93-101.
14.	Thornalley PJ. Disturbance of thiamine metabolism in diabetes and the development and treatment of diabetic vascular complications. Clin Chem Lab Med, 2012, 50(2): A14.
15.	Thornalley PJ, Babaei-Jadidi R, Al AH, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia, 2007, 50(10): 2164-2170.
16.	Luong KV, Nguyen LT. The impact of thiamine treatment in the diabetes mellitus. J Clin Med Res, 2012, 4(3): 153-160.
17.	Riaz S. Study of protein biomarkers of diabetes mellitus type 2 and therapy with vitamin B1. J Diabetes Res, 2015, 2015: 150176.
18.	Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 2014, 14: 135.
19.	Hozo SP, Djulbegovic BHozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 2005, 5: 13.
20.	Alaei-Shahmiri F, Soares MJ, Zhao Y, et al. The impact of thiamine supplementation on blood pressure, serum lipids and C-reactive protein in individuals with hyperglycemia: a randomised, double-blind cross-over trial. Diabetes Metab Syndr, 2015, 9(4): 213-217.
21.	Al-Attas O, Al-Daghri N, Alokail M, et al. Metabolic benefits of six-month thiamine supplementation in patients with and without diabetes mellitus type 2. Clin Med Insights Endocrinol Diabetes, 2014, 7: 1-6.
22.	张秉涛. 维生素B1对2型糖尿病患者尿白蛋白的影响. 中国误诊学杂志, 2011, 11(15): 3577-3578.
23.	Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, et al. Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naive patients with type 2 diabetes. Eur J Nutr, 2011, 50(2): 145-149.
24.	Rabbani N, Alam SS, Riaz S, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia, 2009, 52(2): 208-212.
25.	Alaei-Shahmiri F, Soares MJ, Zhao Y, et al. High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over trial. Eur J Nutr, 2013, 52(7): 1821-1824.
26.	Ge Q, Chen L, Chen K. Treatment of diabetes mellitus using iPS cells and spice polyphenols. J Diabetes Res, 2017, 2017: 5837804.
27.	Alcazar-Leyva S, Alvarado-Vasquez N. Could thiamine pyrophosphate be a regulator of the nitric oxide synthesis in the endothelial cell of diabetic patients? Med Hypotheses, 2011, 76(5): 629-631.
28.	Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Current diabetes reviews, 2005, 1(3): 287-298.
29.	Page GL, Laight D, Cummings MH. Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease. Int J Clin Pract, 2011, 65(6): 684-690.
30.	Jenco J, Krcmova LK, Solichova D, et al. Recent trends in determination of thiamine and its derivatives in clinical practice. J Chromatogr A, 2017, 1510: 1-12.
31.	Adiels M, Olofsson SO, Taskinen MR, et al. Diabetic dyslipidaemia. Curr Opin Lipidol, 2006, 17(3): 238-46.
32.	Karachalias N, Babaei-Jadidi R, Kupich C, et al. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci, 2005, 1043: 777-783.
33.	李斌, 刘恒明. 硫胺素类药物治疗糖尿病微血管病变研究进展. 医药导报, 2007, 26(2): 177-179.
34.	Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med, 1995, 155(7): 701-709.
35.	Laveti D, Kumar M, Hemalatha R, et al. Anti-inflammatory treatments for chronic diseases: a review. Inflamm Allergy Drug Targets, 2013, 12(5): 349-361.
36.	Pfutzner A, Schondorf T, Hanefeld M, et al. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol, 2010, 4(3): 706-716.
37.	Tang Y, Fung E, Xu A, et al. C-reactive protein and ageing. Clin Exp Pharmacol Physiol, 2017, 44(Suppl 1): 9-14.
38.	Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc, 2008, 83(3): 333-342.
39.	Zaringhalam J, Akbari A, Zali A, et al. Long-term treatment by vitamin B1 and reduction of serum proinflammatory cytokines, hyperalgesia, and paw edema in adjuvant-induced arthritis. Basic Clin Neurosci, 2016, 7(4): 331-340.
40.	Ghashut RA, McMillan DC, Kinsella J, et al. Erythrocyte concentrations of B1, B2, B6 but not plasma C and E are reliable indicators of nutrition status in the presence of systemic inflammation. Clin Nutr, 2017, 17: 54-62.
41.	宋璐璐, 杨文英. 维生素B1防治糖尿病微血管并发症. 药品评价, 2009, 6(1): 26-27.
42.	Nath A, Tran T, Shope TR, et al. Prevalence of clinical thiamine deficiency in individuals with medically complicated obesity. Nutr Res, 2017, 37: 29-36.
43.	张培红, 杜琰. 维生素B1、B2与2型糖尿病的关系. 上海预防医学, 2013, (6): 320-321.
44.	Valdes-Ramos R, Guadarrama-Lopez AL, Martinez-Carrillo BE, et al. Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets, 2015, 15(1): 54-63.

1. Unnikrishnan R, Pradeepa R, Joshi SR, et al. Type 2 diabetes: demystifying the global epidemic. Diabetes, 2017, 66(6): 1432-1442.
2. Dixon CJ, Knight T, Binns E, et al. Clinical measures of balance in people with type two diabetes: A systematic literature review. Gait Posture, 2017, 58: 325-332.
3. Zabetian A, Sanchez IM, Narayan KM, et al. Global rural diabetes prevalence: a systematic review and meta-analysis covering 1990-2012. Diabetes Res Clin Pract, 2014, 104(2): 206-213.
4. Wu C, Qiu S, Zhu X, et al. Vitamin D supplementation and glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Metabolism, 2017, 73: 67-76.
5. Garcia-Chapa EG, Leal-Ugarte E, Peralta-Leal V, et al. Genetic epidemiology of type 2 diabetes in Mexican Mestizos. Biomed Res Int, 2017, 2017: 3937893.
6. 王海鹏. 我国诊断糖尿病疾病经济负担趋势预测研究. 济南: 山东大学, 2013.
7. Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic pattern of diabetes and prediabetes in China in 2013. JAMA, 2017, 317(24): 2515-2523.
8. Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes, 2017, 9(4): 320.
9. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care, 2015, 38(Suppl): S8-S16.
10. Gheibi S, Kashfi K, Ghasemi A. A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin. Biomed Pharmacother, 2017, 95: 605-613.
11. Sun W, Zhai M, Zhou Q, et al. Effects of B Vitamins overload on plasma insulin level and hydrogen peroxide generation in rats. Chin J Physiol, 2017, 60(4): 207-214.
12. Nix WA, Zirwes R, Bangert V, et al. Vitamin B status in patients with type 2 diabetes mellitus with and without incipient nephropathy. Diabetes Res Clin Pract, 2015, 107(1): 157-165.
13. Cetin E, Civelek S, Andican G, et al. Plasma AGE-peptides and C-peptide in early-stage diabetic nephropathy patients on thiamine and pyridoxine therapy. Minerva Med, 2013, 104(1): 93-101.
14. Thornalley PJ. Disturbance of thiamine metabolism in diabetes and the development and treatment of diabetic vascular complications. Clin Chem Lab Med, 2012, 50(2): A14.
15. Thornalley PJ, Babaei-Jadidi R, Al AH, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia, 2007, 50(10): 2164-2170.
16. Luong KV, Nguyen LT. The impact of thiamine treatment in the diabetes mellitus. J Clin Med Res, 2012, 4(3): 153-160.
17. Riaz S. Study of protein biomarkers of diabetes mellitus type 2 and therapy with vitamin B1. J Diabetes Res, 2015, 2015: 150176.
18. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 2014, 14: 135.
19. Hozo SP, Djulbegovic BHozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol, 2005, 5: 13.
20. Alaei-Shahmiri F, Soares MJ, Zhao Y, et al. The impact of thiamine supplementation on blood pressure, serum lipids and C-reactive protein in individuals with hyperglycemia: a randomised, double-blind cross-over trial. Diabetes Metab Syndr, 2015, 9(4): 213-217.
21. Al-Attas O, Al-Daghri N, Alokail M, et al. Metabolic benefits of six-month thiamine supplementation in patients with and without diabetes mellitus type 2. Clin Med Insights Endocrinol Diabetes, 2014, 7: 1-6.
22. 张秉涛. 维生素B1对2型糖尿病患者尿白蛋白的影响. 中国误诊学杂志, 2011, 11(15): 3577-3578.
23. Gonzalez-Ortiz M, Martinez-Abundis E, Robles-Cervantes JA, et al. Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naive patients with type 2 diabetes. Eur J Nutr, 2011, 50(2): 145-149.
24. Rabbani N, Alam SS, Riaz S, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia, 2009, 52(2): 208-212.
25. Alaei-Shahmiri F, Soares MJ, Zhao Y, et al. High-dose thiamine supplementation improves glucose tolerance in hyperglycemic individuals: a randomized, double-blind cross-over trial. Eur J Nutr, 2013, 52(7): 1821-1824.
26. Ge Q, Chen L, Chen K. Treatment of diabetes mellitus using iPS cells and spice polyphenols. J Diabetes Res, 2017, 2017: 5837804.
27. Alcazar-Leyva S, Alvarado-Vasquez N. Could thiamine pyrophosphate be a regulator of the nitric oxide synthesis in the endothelial cell of diabetic patients? Med Hypotheses, 2011, 76(5): 629-631.
28. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Current diabetes reviews, 2005, 1(3): 287-298.
29. Page GL, Laight D, Cummings MH. Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease. Int J Clin Pract, 2011, 65(6): 684-690.
30. Jenco J, Krcmova LK, Solichova D, et al. Recent trends in determination of thiamine and its derivatives in clinical practice. J Chromatogr A, 2017, 1510: 1-12.
31. Adiels M, Olofsson SO, Taskinen MR, et al. Diabetic dyslipidaemia. Curr Opin Lipidol, 2006, 17(3): 238-46.
32. Karachalias N, Babaei-Jadidi R, Kupich C, et al. High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats. Ann N Y Acad Sci, 2005, 1043: 777-783.
33. 李斌, 刘恒明. 硫胺素类药物治疗糖尿病微血管病变研究进展. 医药导报, 2007, 26(2): 177-179.
34. Cook NR, Cohen J, Hebert PR, et al. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med, 1995, 155(7): 701-709.
35. Laveti D, Kumar M, Hemalatha R, et al. Anti-inflammatory treatments for chronic diseases: a review. Inflamm Allergy Drug Targets, 2013, 12(5): 349-361.
36. Pfutzner A, Schondorf T, Hanefeld M, et al. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol, 2010, 4(3): 706-716.
37. Tang Y, Fung E, Xu A, et al. C-reactive protein and ageing. Clin Exp Pharmacol Physiol, 2017, 44(Suppl 1): 9-14.
38. Dandona P. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin Proc, 2008, 83(3): 333-342.
39. Zaringhalam J, Akbari A, Zali A, et al. Long-term treatment by vitamin B1 and reduction of serum proinflammatory cytokines, hyperalgesia, and paw edema in adjuvant-induced arthritis. Basic Clin Neurosci, 2016, 7(4): 331-340.
40. Ghashut RA, McMillan DC, Kinsella J, et al. Erythrocyte concentrations of B1, B2, B6 but not plasma C and E are reliable indicators of nutrition status in the presence of systemic inflammation. Clin Nutr, 2017, 17: 54-62.
41. 宋璐璐, 杨文英. 维生素B1防治糖尿病微血管并发症. 药品评价, 2009, 6(1): 26-27.
42. Nath A, Tran T, Shope TR, et al. Prevalence of clinical thiamine deficiency in individuals with medically complicated obesity. Nutr Res, 2017, 37: 29-36.
43. 张培红, 杜琰. 维生素B1、B2与2型糖尿病的关系. 上海预防医学, 2013, (6): 320-321.
44. Valdes-Ramos R, Guadarrama-Lopez AL, Martinez-Carrillo BE, et al. Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets, 2015, 15(1): 54-63.

Previous Article
Diagnostic value of ICTP for bone metastases of lung cancer: a meta-analysis
Next Article
The perinatal outcomes after laparoscopic myomectomy versus transabdominal myomectomy: a meta-analysis

Chinese Journal of Evidence-Based Medicine

Therapeutic efficacy of vitamin B₁ for adjunctive treatment in type 2 diabetes mellitus: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Chinese Journal of Evidence-Based Medicine

Therapeutic efficacy of vitamin B1 for adjunctive treatment in type 2 diabetes mellitus: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content

Therapeutic efficacy of vitamin B₁ for adjunctive treatment in type 2 diabetes mellitus: a meta-analysis